Lexicon Pharmaceuticals Inc
$ 1.72
-2.27%
10 Apr - close price
- Market Cap 728,731,000 USD
- Current Price $ 1.72
- High / Low $ 1.80 / 1.70
- Stock P/E N/A
- Book Value 0.30
- EPS -0.14
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.40 %
- 52 Week High 1.84
- 52 Week Low 0.48
About
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of pharmaceutical products. The company is headquartered in The Woodlands, Texas.
Analyst Target Price
$3.36
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-05 | 2025-11-06 | 2025-08-06 | 2025-04-30 | 2025-03-10 | 2024-11-06 | 2024-08-01 | 2024-05-02 | 2024-03-11 | 2023-11-08 | 2023-08-03 | 2023-05-02 |
| Reported EPS | -0.04 | -0.04 | 0.01 | -0.07 | -0.09 | -0.18 | -0.17 | -0.2 | -0.2 | -0.21 | -0.22 | -0.17 |
| Estimated EPS | -0.067 | -0.07 | -0.09 | -0.1033 | -0.1248 | -0.16 | -0.19 | -0.2 | -0.22 | -0.21 | -0.17 | -0.18 |
| Surprise | 0.027 | 0.03 | 0.1 | 0.0333 | 0.0348 | -0.02 | 0.02 | 0 | 0.02 | 0 | -0.05 | 0.01 |
| Surprise Percentage | 40.2985% | 42.8571% | 111.1111% | 32.2362% | 27.8846% | -12.5% | 10.5263% | 0% | 9.0909% | 0% | -29.4118% | 5.5556% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.04 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LXRX
2026-04-11 01:38:44
This page provides access to Lexicon Pharmaceuticals Inc.'s (NASDAQ: LXRX) official regulatory documents filed with the U.S. Securities and Exchange Commission, including 10-K annual reports, 10-Q quarterly reports, and 8-K material event filings. It details recent insider transactions, such as significant equity awards to executives and major share purchases by investment entities like Invus and Artal, which are increasing their stake in the company. The page also highlights Lexicon's financing activities, including public stock offerings and private placements, aimed at funding its biopharmaceutical operations and pipeline development.
2026-04-03 16:10:23
This page provides a comprehensive resource for Lexicon Pharmaceuticals (LXRX) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It details the company's financial condition, capital-raising activities, and drug pipeline developments, supplemented with AI-powered summaries and impact analysis for each filing. The article highlights recent activities such as stock sale plans, milestone payments from licensing agreements, and clinical trial progress for its various drug candidates.
2026-04-02 16:39:16
Lexicon Pharmaceuticals participated as a sponsor in the 2026 Texas Life Sciences Summit, engaging with industry leaders and innovators to foster optimism and momentum within the sector. The company also recently announced advancements in non-opioid chronic pain treatments and presented new SOTA‑P‑CARDIA Chapter 2 trial data for HFpEF at the ACC26 conference. These engagements underscore Lexicon's commitment to strengthening its presence and driving innovation in life sciences.
2026-04-02 14:09:50
This article provides a technical analysis and stock price forecast for Lexicon Pharmaceuticals Inc (LXRX), indicating a Neutral technical sentiment based on an aggregation of 9 technical signals. The analysis covers momentum indicators like RSI and MACD, support and resistance levels, and various moving averages. As of April 2, 2026, LXRX is trading above its 60-day and 200-day moving averages, while its RSI suggests a neutral condition.
2026-04-01 22:09:55
This page provides a comprehensive resource for investors to access Lexicon Pharmaceuticals (NASDAQ: LXRX) SEC filings, including annual 10-K, quarterly 10-Q, and material event 8-K reports. It highlights recent compliance updates with Nasdaq listing rules, such as restoring compliance and obtaining grace periods to avoid delisting. The platform also offers AI-powered summaries and real-time updates for better investor understanding.
2026-03-31 21:12:31
Certain Restricted Stock Units (RSUs) of Lexicon Pharmaceuticals, Inc. are under a lock-up agreement set to expire on April 1, 2026. This lock-up period, which began on January 30, 2026, restricts officers, directors, and a private placement purchaser from selling or transferring these RSUs for 61 days without prior written consent. The agreement aims to prevent market instability caused by immediate selling after certain corporate events.
